

This section of the global Janssen website provides a company overview in several languages. It is not targeted to any specific audience or country. Click [here](#) for country- and region-specific information of interest.



JANSSEN GLOBAL
[change location >](#)

MEDIA CONTACT:

Katie Buckley

+44 7971 956 179

kbuckle8@its.jnj.com

INVESTOR RELATIONS:

Lesley Fishman

+1 732-524-3922

lfishma@its.jnj.com

References

1. Janssen. INCIVO[®] Approved in Europe Approved In Europe Offering High Cure Rates for Genotype-1 Chronic Hepatitis C Compared to Standard of Care. Available at: <https://www.jnj.com/media-center/press-releases/incivo-telaprevir-approved-in-europe-offering-higher-cure-rates-for-genotype-1-chronic-hepatitis-c-compared-to-standard-treatment> Last accessed: September 2017.
2. Janssen. OLYSIO[™] (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C. Available at: <https://www.jnj.com/media-center/press-releases/olysio-simeprevir-receives-fda-approval-for-combination-treatment-of-chronic-hepatitis-c> Last accessed: September 2017
3. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. *Journal of Hepatology*. 2017; 66(1):153-194.

PRIVACY POLICY LEGAL NOTICE
CAREERS NEWS CENTER CONTACT US

FIND JANSSEN GLOBAL ON:

This section of the global Janssen website provides a company overview in several languages. It is not targeted to any specific audience or country. Click [here](#) for country- and region-specific information of interest.



[JANSSEN GLOBAL](#)
[change location >](#)

countries is identified where it appears. All third-party trademarks used herein are registered trademarks of their respective owners. Last Updated: September 14, 2017